A Robust Pipeline for the Future
Ipsen’s R&D activities are focused on discovering and developing new molecules and programs for the lifecycle management of products already marketed by the company (including new formulations, extension of indications, and registration of products in new geographical areas).
We are dedicated to making meaningful strides in oncology by applying Ipsen’s successful R&D approach focused on peptides and toxins, translational research, and strategic partnerships. Our molecules in testing are developed by a combination of applying functional insights from basic science research with leveraging our technical expertise and the knowledge base of our partners. We are particularly interested in drugs with new mechanisms of action, as embodied by our tasquinimod partnership with Active Biotech.
Current areas of worldwide research in oncology: neuroendocrine tumors and prostate, hepatocellular, ovarian, renal cell, and gastric cancers.